摘要
银屑病是一种病因尚未明确的慢性炎症性皮肤病。目前有研究发现,酪氨酸蛋白激酶(JAK)/信号转导因子和转录激活因子(STAT)信号转导通路在银屑病发生发展过程中有重要影响。托法替尼(tofacitinib)是一种新型的小分子口服酪氨酸激酶抑制剂,主要作用于JAK/STAT信号通路,具有抗炎、抗增殖、调节免疫作用。美国食品药品管理局(FDA)已将其批准用于成人的中重度活动性类风湿性关节炎(RA)、溃疡性结肠炎(UC)及活动性关节病型银屑病(PsA)的治疗。国内外研究表明,托法替尼在治疗多种与免疫相关的皮肤病中也取得了较好疗效,如斑块型银屑病、斑秃、特应性皮炎、白癜风等。特别是在斑块型银屑病的治疗方面,托法替尼有较好的应用前景。本文分析了托法替尼在银屑病治疗方面的最新研究进展。
Psoriasis is a chronic inflammatory skin disease,the exact cause of which is not yet clear.At present,researchers have found that Janus kinase(JAK)/signal transducer and activator of transcription(STAT)signal transduction pathway have important effects on the occurrence and development of psoriasis.Tofacitinib is a new type of small molecule oral tyrosine kinase inhibitor,which mainly acts on JAK/STAT signal pathway and has anti-inflammatory,anti-proliferation and immune regulating effects.The U.S.Food and Drug Administration(FDA)has approved it for the treatment of moderate to severe active rheumatoid arthritis(RA),ulcerative colitis(UC)and active arthropathy psoriasis(PsA)in adults.Studies at home and abroad showed that tofacitinib has also achieved good therapeutic effects in the treatment of various imm-une-related skin diseases,such as plaque psoriasis,alopecia areata,atopic dermatitis,vitiligo,etc.Especially in the treatment of plaque psoriasis,tofacitinib has a good application prospect.This article tries to analyze the latest research progress of tofacitinib in the treatment of psoriasis.
作者
刘绿野
耿立东
LIU Lyv-ye;GENG Li-dong(Shandong University of Traditional Chinese Medicine,Jinan 250014,China;Department of Dermatology,Shandong Provincial Hospital of Traditional Chinese Medicine,Jinan 250014,China)
出处
《临床药物治疗杂志》
2022年第3期22-26,共5页
Clinical Medication Journal
作者简介
通信作者:耿立东,大学本科,主任医师,教授,研究方向:中西医结合皮肤性病治疗研究。E-mail:lly4491@163.com。
